+38.6% · 90d
$31.24
+0.51 (+1.64%)
News
(1)April 2026
LBRX Reports $126.5M Cash for LB-102 Phase 3 Schizophrenia Trial
LBRXLB PHARMACEUTICALS INC
# 🧾 What This Document Is This is LB Pharmaceuticals' **Annual Report to Shareholders (ARS)**. Think of it as the company's yearly "report card" sent directly to its owners. It's a comprehensive but more reader-friendly summary of their performance, strategy, and financial health compared to a dens
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%